Johnson & Johnson (JNJ)
Johnson & Johnson CEO: 'We're in the Golden Era of Medical Innovation'
Johnson & Johnson Chairman and CEO Joaquin Duato believes that we are now in a “golden era” of innovation, particularly in the United States. Venture capital plays a vital early-stage role, but big pharma provides the infrastructure and market access.
Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 11, 2025 3:20 PM ET Company Participants Tom Cavanaugh - Company Group Chairman for North America Innovative Medicine Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider We're just right about at time, so let's get started. Tail end of day 3 of our conference, saving the best for last.
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
Top 3 dividend stocks to buy for 2026
Holding dividend stocks remains one of the most effective long-term strategies, with companies that pay a regular dividend often being profitable and well-positioned for future growth, even during economic downturns.
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
Johnson & Johnson (JNJ) closed at $154.42 in the latest trading session, marking a -0.63% move from the prior day.
Is Merck Stock About To Crash?
Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average revenue growth compared to J&J's modest 4%, and Merck's operating cash flow margins are a healthier 33% versus J&J's 28%.
Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market
Johnson & Johnson remains undervalued with strong profitability and reasonable valuation metrics, but growth prospects are modest and uncertain. Profitability is robust, with an A+ grade, high margins, and nearly 30% return on equity, supporting the company's structural quality. Key risks include regulatory challenges, legal liabilities from talc lawsuits, and potential price controls on major drugs like Darzalex Faspro.
These 2 Dividend Stocks Have Grown Dividends For 50 Consecutive Years. Can That Streak Continue?
It may be too soon to rotate back into the risk trade as market volatility calms.
Johnson & Johnson: Dividend King On Sale Yielding Over 3% And Undervalued
Despite legal headwinds and a declining share price, JNJ remains a financial powerhouse with strong profitability, a robust dividend, and aggressive buybacks. JNJ's 62-year streak of dividend growth, 3.4% yield, and disciplined capital allocation make it highly attractive for long-term, income-focused investors. The company is undervalued, trading at less than 15x 2025 EPS, with double-digit EPS growth projected and a pipeline of high-growth assets fueling future expansion.
